Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 20 of 20 publications.

Brufsky A, Kwan ML, Sandin R, Stergiopoulos S, Karanth S, Cha-Silva AS, Makari D, Goyal RK. Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2− and HER2+ metastatic breast cancer. Breast Cancer Res Treat. 2024 Nov;208(2):223-35. doi: 10.1007/s10549-024-07469-6

Goyal RK, Zhang J, Davis KL, Sluga-O'Callaghan M, Kaufman PA. Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-kinase inhibitor treatment for metastatic breast cancer. Breast Cancer Res Treat. 2024 May;205(1):201-10. doi: 10.1007/s10549-023-07080-1

Wang Z, Whipp AM, Heinonen-Guzejev M, Foraster M, Julvez J, Kaprio J. The association between urban land use and depressive symptoms in young adulthood: a FinnTwin12 cohort study. J Expo Sci Environ Epidemiol. 2023 Dec 11. doi: 10.1038/s41370-023-00619-w

Goyal RK, Holmes HM, Chen H, Abughosh S, Candrilli SD, Johnson ML. Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2- metastatic breast cancer in the United States. Breast Cancer Res Treat. 2023 Feb;198(1):159-66. doi: 10.1007/s10549-022-06845-4

Perez EA, Dang C, Lee C, Singh J, Wang K, Layton JB, Gilsenan A, Hackshaw MD, Cortes J. Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review. Breast Cancer Res Treat. 2022 Jul;194(1):1-11. doi: 10.1007/s10549-021-06469-0

Richardson D, Zhan L, Mahtani R, McRoy L, Mitra D, Reynolds M, Odom D, Hollis K, Kaye JA, Jones C, Hargis J. A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application. Breast Cancer Res Treat. 2021 May;187(1):113-24. doi: 10.1007/s10549-020-06082-7

Stenehjem DD, Telford C, Unni SK, Bauer H, Sainski A, Deka R, Schauerhamer MB, Ye X, Tak CR, Ma J, Dalvi TB, Gutierrez L, Kaye JA, Tyczynski JE, Brixner DI, Biskupiak JE. BRCA testing and outcomes in women with breast cancer. Breast Cancer Res Treat. 2021 Apr;186(3):839-50. doi: 10.1007/s10549-020-06038-x

Sauchelli S, Bradley J, Cox J, England C, Perry R. Weight maintenance interventions for people with type 2 diabetes mellitus: a systematic review protocol. Syst Rev. 2020 Sep 12;9(1):210. doi: 10.1186/s13643-020-01467-7

Hackshaw MD, Danysh HE, Singh J, Ritchey ME, Ladner A, Taitt C, Camidge DR, Powell CA. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2020 Jun 26;183(1):23-39. doi: 10.1007/s10549-020-05754-8

Liede A, Mansfield CA, Metcalfe KA, Price MA, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Snyder C, Lynch HT, Friedman S, Amelio J, Posner J, Narod SA, Lindeman GJ, Evans DG. Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment. Breast Cancer Res Treat. 2017 Sep;165(2):433-44. doi: 10.1007/s10549-017-4332-3.

Hunter JE, Arnold KA, Cook JE, Zepp J, Gilmore MJ, Rope AF, Davis JV, Bergen KM, Esterberg E, Muessig KR, Peterson SK, Syngal S, Acheson L, Wiesner G, Reiss J, Goddard KAB. Universal screening for Lynch syndrome among patients with colorectal cancer: patient perspectives on screening and sharing results with at-risk relatives. Fam Cancer. 2017 Jul;16(3):377-87. doi: 10.1007/s10689-017-9972-2

Demeyin (Nuabor) WA, Frost J, Ukoumunne OC, Briscoe S, Britten N. N of 1 trials and the optimal individualisation of drug treatments: a systematic review protocol. Syst Rev. 2017 Apr 24;6(1):90. doi: 10.1186/s13643-017-0479-6

Danysh HE, Mitchell LE, Zhang K, Scheurer ME, Lupo PJ. Differences in environmental exposure assignment due to residential mobility among children with a central nervous system tumor: Texas, 1995-2009. J Expo Sci Environ Epidemiol. 2017 Jan;27(1):41-6. doi: 10.1038/jes.2015.63

Cole-Hunter T, Weichenthal S, Kubesch N, Foraster M, Carrasco-Turigas G, Bouso L, Martinez D, Westerdahl D, de Nazelle A, Nieuwenhuijsen M. Impact of traffic-related air pollution on acute changes in cardiac autonomic modulation during rest and physical activity: a cross-over study. J Expo Sci Environ Epidemiol. 2016 Mar;26(2):133-40. doi: 10.1038/jes.2015.66

Dine JL, O'Sullivan CC, Voeller D, Greer YE, Chavez KJ, Conway CM, Sinclair S, Stone B, Amiri-Kordestani L, Merchant AS, Hewitt SM, Steinberg SM, Swain SM, Lipkowitz S. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. Breast Cancer Res Treat. 2016 Jan;155(2):235-51. doi: 10.1007/s10549-015-3673-z.

Aguilera I, Foraster M, Basagana X, Corradi E, Deltell A, Morelli X, Phuleria HC, Ragettli MS, Rivera M, Thomasson A, Slama R, Kunzli N. Application of land use regression modelling to assess the spatial distribution of road traffic noise in three European cities. J Expo Sci Environ Epidemiol. 2015 Jan;25(1):97-105. doi: 10.1038/jes.2014.61

Huang K, Gutierrez LP, Bulow S, Gallinger S, Castells A, Eagle CJ, Church JM. Clinical characteristics and outcomes in familial adenomatous polyposis patients with a long-term treatment of celecoxib: a matched cohort study. Fam Cancer. 2011 Jun 1;10(2):303-8.

Blum JL, Kohles J, McKenna E, Scotto N, Hu S, Odom D, Kaye JA, Glück S. Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials. Breast Cancer Res Treat. 2011 Jan 1;125(2):431-9.

Zhou X, Cella D, Cameron D, Amonkar MM, Segreti A, Stein S, Walker M, Geyer CE. Lapatinib plus capecitabine versus capecitabine alone for HER2+(ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat. 2009 Oct 1;117(3):577-89. doi: 10.1007/s10549-009-0310-8

Yost KJ, Yount SE, Eton DT, Silberman C, Broughton-Heyes A, Cella D. Validation of the Functional assessment of cancer therapy-Breast Symptom Index (FBSI). Breast Cancer Res Treat. 2005 Apr 1;90(3):295-8.